Retatrutide Dosing Protocol: 10 mg Vial — Week-by-Week Titration & Supplies
给药方案详解
以下方案内容整理自公开资料与临床文献，仅供研究参考，不构成医疗建议。
Quickstart highlights
Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, producing 24.2% mean body weight reduction at 12 mg weekly in Phase 2 (NCT04881760).
- Concentration: 5 mg/mL (10 mg vial + 2 mL bacteriostatic water).
- At 5 mg/mL: 1 mg = 20 units, 4 mg = 80 units, 8 mg = 160 units (requires 3 mL syringe for 1.6 mL volume).
- Phase 2 trial: 8 mg arm achieved approximately 22% body weight reduction at 48 weeks.
- One 10 mg vial covers all of weeks 1–4 at 1 mg/dose, with volume remaining for partial week 5–8 dosing.
- Refrigerate; use within 28 days of reconstitution.
Dosing table
For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.
| Week | Dose (µg) | Units | Frequency | Notes |
|---|---|---|---|---|
| 1-4 | 1000 | 20 | Once weekly | 1 mg — 20 units; 10 mg vial provides 10 starting doses |
| 5-8 | 2000 | 40 | Once weekly | 2 mg — 40 units; 5 doses remaining per vial |
| 9-12 | 4000 | 80 | Once weekly | 4 mg — 80 units; vial provides ~2.5 doses |
| 13-16 | 8000 | 160 | Once weekly | 8 mg — 160 units (1.6 mL); use 3 mL syringe; vial provides ~1.25 doses |
Your free Retatrutide tracker
- Dose reminders
- Injection logging
- Cycle progress
Reconstitution steps
- Draw 2 mL bacteriostatic water; inject slowly down the vial wall.
- Swirl gently until fully dissolved; do not shake.
- Final concentration: 5 mg/mL (10 mg / 2 mL).
- Label with date and concentration; refrigerate at 2–8 °C immediately.
Supplies needed
8-week plan
- 1 vial
- 8 syringes
- 2 mL bac water
- 8 alcohol swabs
12-week plan
- 2 vials
- 12 syringes
- 4 mL bac water
- 12 alcohol swabs
16-week plan
- 3 vials
- 16 syringes
- 6 mL bac water
- 16 alcohol swabs
Protocol overview & cycle notes
Provide a 12–16 week retatrutide titration cycle using the 10 mg vial as the primary supply, enabling efficient progression from 1 mg to 8 mg maintenance without frequent vial changes.
Cycle length: 16 weeks on.
Off-cycle: 8–12 weeks off between cycles.
Storage & handling
Injection & tracking tips
- Use a 3 mL syringe for the 8 mg dose (1.6 mL); a standard 1 mL U-100 syringe is insufficient.
- Rotate injection sites weekly: abdomen (preferred), outer thigh, upper arm.
- Drink ≥2.5 L water daily — glucagon agonism increases urinary water loss at higher doses.
Tracking
Logging helps you and your provider spot patterns and adjust dose or timing.
- Log weekly body weight and fasted waist circumference.
- Track nausea (0–10 scale) after each injection for the first 12 weeks.
- Monitor fasting glucose weekly; glucagon effects may transiently elevate fasting blood sugar.
How this works & references
Sources
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. Jastreboff AM et al. — N Engl J Med — 2023
- TRIUMPH Phase 3 program (NCT05668520) — ongoing trials
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Rosenstock J et al. — Lancet — 2023
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Coskun T et al. — Lancet Diabetes Endocrinol — 2025
Frequently asked questions
How do I draw 1.6 mL from the vial for the 8 mg dose?
When will retatrutide be FDA-approved?
Is the 10 mg vial the best size for the full titration?
What distinguishes retatrutide from semaglutide and tirzepatide?
Does retatrutide cause thyroid cancer risk like GLP-1 agonists?
Related protocols
KLOW Blend Dosing Protocol — BPC-157, TB-500, KPV & GHK-Cu Guide
KLOW peptide blend (BPC-157 + TB-500 + KPV + GHK-Cu) dosing guide for tissue repair, anti-inflammatory support, and extracellular matrix remodeling — the GLOW blend plus KPV.
View protocolGLOW Blend Dosing Protocol — BPC-157, TB-500 & GHK-Cu Skin & Repair Guide
GLOW peptide blend (BPC-157 + TB-500 + GHK-Cu) dosing guide for tissue repair, angiogenesis, and collagen and connective-tissue remodeling.
View protocolVilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide
Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.
View protocolVesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide
Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.
View protocolThis content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.
Quickstart highlights
Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, producing 24.2% mean body weight reduction at 12 mg weekly in Phase 2 (NCT04881760).
- Concentration: 5 mg/mL (10 mg vial + 2 mL bacteriostatic water).
- At 5 mg/mL: 1 mg = 20 units, 4 mg = 80 units, 8 mg = 160 units (requires 3 mL syringe for 1.6 mL volume).
- Phase 2 trial: 8 mg arm achieved approximately 22% body weight reduction at 48 weeks.
- One 10 mg vial covers all of weeks 1–4 at 1 mg/dose, with volume remaining for partial week 5–8 dosing.
- Refrigerate; use within 28 days of reconstitution.
Dosing table
For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.
| Week | Dose (µg) | Units | Frequency | Notes |
|---|---|---|---|---|
| 1-4 | 1000 | 20 | Once weekly | 1 mg — 20 units; 10 mg vial provides 10 starting doses |
| 5-8 | 2000 | 40 | Once weekly | 2 mg — 40 units; 5 doses remaining per vial |
| 9-12 | 4000 | 80 | Once weekly | 4 mg — 80 units; vial provides ~2.5 doses |
| 13-16 | 8000 | 160 | Once weekly | 8 mg — 160 units (1.6 mL); use 3 mL syringe; vial provides ~1.25 doses |
Your free Retatrutide tracker
- Dose reminders
- Injection logging
- Cycle progress
Reconstitution steps
- Draw 2 mL bacteriostatic water; inject slowly down the vial wall.
- Swirl gently until fully dissolved; do not shake.
- Final concentration: 5 mg/mL (10 mg / 2 mL).
- Label with date and concentration; refrigerate at 2–8 °C immediately.
Supplies needed
8-week plan
- 1 vial
- 8 syringes
- 2 mL bac water
- 8 alcohol swabs
12-week plan
- 2 vials
- 12 syringes
- 4 mL bac water
- 12 alcohol swabs
16-week plan
- 3 vials
- 16 syringes
- 6 mL bac water
- 16 alcohol swabs
Protocol overview & cycle notes
Provide a 12–16 week retatrutide titration cycle using the 10 mg vial as the primary supply, enabling efficient progression from 1 mg to 8 mg maintenance without frequent vial changes.
Cycle length: 16 weeks on.
Off-cycle: 8–12 weeks off between cycles.
Storage & handling
Injection & tracking tips
- Use a 3 mL syringe for the 8 mg dose (1.6 mL); a standard 1 mL U-100 syringe is insufficient.
- Rotate injection sites weekly: abdomen (preferred), outer thigh, upper arm.
- Drink ≥2.5 L water daily — glucagon agonism increases urinary water loss at higher doses.
Tracking
Logging helps you and your provider spot patterns and adjust dose or timing.
- Log weekly body weight and fasted waist circumference.
- Track nausea (0–10 scale) after each injection for the first 12 weeks.
- Monitor fasting glucose weekly; glucagon effects may transiently elevate fasting blood sugar.
How this works & references
Sources
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. Jastreboff AM et al. — N Engl J Med — 2023
- TRIUMPH Phase 3 program (NCT05668520) — ongoing trials
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Rosenstock J et al. — Lancet — 2023
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Coskun T et al. — Lancet Diabetes Endocrinol — 2025
Frequently asked questions
How do I draw 1.6 mL from the vial for the 8 mg dose?
When will retatrutide be FDA-approved?
Is the 10 mg vial the best size for the full titration?
What distinguishes retatrutide from semaglutide and tirzepatide?
Does retatrutide cause thyroid cancer risk like GLP-1 agonists?
Related protocols
KLOW Blend Dosing Protocol — BPC-157, TB-500, KPV & GHK-Cu Guide
KLOW peptide blend (BPC-157 + TB-500 + KPV + GHK-Cu) dosing guide for tissue repair, anti-inflammatory support, and extracellular matrix remodeling — the GLOW blend plus KPV.
View protocol
GLOW Blend Dosing Protocol — BPC-157, TB-500 & GHK-Cu Skin & Repair Guide
GLOW peptide blend (BPC-157 + TB-500 + GHK-Cu) dosing guide for tissue repair, angiogenesis, and collagen and connective-tissue remodeling.
View protocol
Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide
Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.
View protocol
Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide
Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.
View protocol
This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.